ICPT Share Price

Open 124.44 Change Price %
High 126.89 1 Day -2.66 -2.12
Low 122.18 1 Week -7.06 -5.44
Close 122.79 1 Month 17.57 16.70
Volume 396251 1 Year 3.50 2.93
52 Week High 177.93
52 Week Low 96.63
ICPT Important Levels
Resistance 2 127.16
Resistance 1 125.36
Pivot 123.95
Support 1 120.22
Support 2 118.42
NASDAQ USA Most Active Stocks
CTRP 47.59 1.13%
ADBE 119.47 -0.13%
FSLR 33.57 -8.33%
FSLR 33.57 -8.33%
CERN 55.37 0.18%
BIDU 186.01 0.21%
AAPL 137.11 0.30%
AAPL 137.11 0.30%
FB 136.12 1.79%
MASI 87.05 2.03%
More..
NASDAQ USA Top Gainers Stocks
VALV 0.05 66.67%
LOCM 0.09 50.00%
BASI 1.33 31.68%
WRES 0.09 28.57%
INAP 2.31 27.62%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
SKBI 0.10 25.00%
AETI 2.40 23.08%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
LLEN 0.01 -50.00%
LIWA 0.01 -50.00%
QTWW 0.08 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
More..

Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT)

ICPT Technical Analysis 1.5
As on 22nd Feb 2017 ICPT Share Price closed @ 122.79 and we RECOMMEND Sell for LONG-TERM with Stoploss of 136.06 & Buy for SHORT-TERM with Stoploss of 110.47 we also expect STOCK to react on Following IMPORTANT LEVELS.
ICPT Target for February
1st Target up-side 117.98
2nd Target up-side 123.75
3rd Target up-side 129.52
1st Target down-side 101.52
2nd Target down-side 95.75
3rd Target down-side 89.98
ICPT Other Details
Segment EQ
Market Capital 330403136.00
Sector Healthcare
Industry Drug Manufacturers - Major
Offical website http://www.interceptpharma.com
ICPT Address
ICPT
450 West 15th Street
New York, NY 10011
United States
Phone: 646-747-1000
Fax: 646-747-1001
Interactive Technical Analysis Chart Intercept Pharmaceuticals, Inc. ( ICPT NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Intercept Pharmaceuticals, Inc.
ICPT Business Profile
Intercept Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver diseases utilizing its bile acid chemistry.The Company�s product candidate, obeticholic acid, or OCA, is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid. It is developing OCA initially for primary biliary cirrhosis, or PBC, as a second line treatment for patients who have an inadequate response to or who are unable to tolerate standard of care therapy and therefore need additional treatment. The Company is conducting a Phase 3 clinical trial of OCA in PBC, which it calls the POISE trial, that serves as the basis for seeking regulatory approval in the United States and Europe. As of December 19, 2012, the Company completed enrollment of the POISE trial with 217 patients.